Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 52 of 52 entries
Sorted by: Best Match Show Resources per page
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.

Clinical pharmacokinetics

Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M.
PMID: 34878624
Clin Pharmacokinet. 2021 Dec 08; doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 08.

BACKGROUND AND OBJECTIVES: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix exposure in healthy women and...

Cite
Beck D, Winzenborg I, Liu M, et al. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01096-w.
Beck, D., Winzenborg, I., Liu, M., Degner, J., Mostafa, N. M., Noertersheuser, P., & Shebley, M. (2021). Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01096-w
Beck, Denise, et al. "Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01096-w
Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2021 Dec 08; doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 08. PMID: 34878624.
Copy Download .nbib Format: NLM
Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study.

Virchows Archiv : an international journal of pathology

Turner BM, Cramer SF, Heller DS, Tavassoli FA.
PMID: 34725735
Virchows Arch. 2021 Nov 02; doi: 10.1007/s00428-021-03225-z. Epub 2021 Nov 02.

Apoplectic leiomyomas-benign uterine leiomyomas with morphologic changes including hemorrhage, hypercellularity, mitotic activity, nuclear atypia, and even necrosis-can be difficult to distinguish from uterine leiomyosarcomas. Apoplectic leiomyomas have been associated with hormonal therapy; however, the relationship between apoplectic leiomyomas, hormones,...

Cite
Turner BM, Cramer SF, Heller DS, et al. Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study. Virchows Arch. 2021;doi: 10.1007/s00428-021-03225-z.
Turner, B. M., Cramer, S. F., Heller, D. S., & Tavassoli, F. A. (2021). Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study. Virchows Archiv : an international journal of pathology, . https://doi.org/10.1007/s00428-021-03225-z
Turner, Bradley M, et al. "Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study." Virchows Archiv : an international journal of pathology vol. (2021). doi: https://doi.org/10.1007/s00428-021-03225-z
Turner BM, Cramer SF, Heller DS, Tavassoli FA. Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study. Virchows Arch. 2021 Nov 02; doi: 10.1007/s00428-021-03225-z. Epub 2021 Nov 02. PMID: 34725735.
Copy Download .nbib Format: NLM
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.

Clinical pharmacokinetics

Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M.
PMID: 34878624
Clin Pharmacokinet. 2021 Dec 08; doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 08.

BACKGROUND AND OBJECTIVES: Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and factors affecting elagolix exposure in healthy women and...

Cite
Beck D, Winzenborg I, Liu M, et al. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2021;doi: 10.1007/s40262-021-01096-w.
Beck, D., Winzenborg, I., Liu, M., Degner, J., Mostafa, N. M., Noertersheuser, P., & Shebley, M. (2021). Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clinical pharmacokinetics, . https://doi.org/10.1007/s40262-021-01096-w
Beck, Denise, et al. "Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids." Clinical pharmacokinetics vol. (2021). doi: https://doi.org/10.1007/s40262-021-01096-w
Beck D, Winzenborg I, Liu M, Degner J, Mostafa NM, Noertersheuser P, Shebley M. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. Clin Pharmacokinet. 2021 Dec 08; doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 08. PMID: 34878624.
Copy Download .nbib Format: NLM
Synthesis of [H-3]- and [C-14]-labeled elagolix.

Journal of labelled compounds & radiopharmaceuticals

Soli ED, Surber BW, Reed AD.
PMID: 33675109
J Labelled Comp Radiopharm. 2021 Jun 15;64(7):254-261. doi: 10.1002/jlcr.3908. Epub 2021 Mar 22.

Gonadotropin-releasing hormone (GnRH) receptor antagonists are an important class of compounds designed to block the pituitary gland from synthesizing follicle-stimulating hormone and luteinizing hormone for the treatment of sex hormone dependent disorders. Elagolix (ABT-620) is currently approved for the...

Cite
Soli ED, Surber BW, Reed AD. Synthesis of [H-3]- and [C-14]-labeled elagolix. J Labelled Comp Radiopharm. 2021;64(7):254-261doi: 10.1002/jlcr.3908.
Soli, E. D., Surber, B. W., & Reed, A. D. (2021). Synthesis of [H-3]- and [C-14]-labeled elagolix. Journal of labelled compounds & radiopharmaceuticals, 64(7), 254-261. https://doi.org/10.1002/jlcr.3908
Soli, Eric D, et al. "Synthesis of [H-3]- and [C-14]-labeled elagolix." Journal of labelled compounds & radiopharmaceuticals vol. 64,7 (2021): 254-261. doi: https://doi.org/10.1002/jlcr.3908
Soli ED, Surber BW, Reed AD. Synthesis of [H-3]- and [C-14]-labeled elagolix. J Labelled Comp Radiopharm. 2021 Jun 15;64(7):254-261. doi: 10.1002/jlcr.3908. Epub 2021 Mar 22. PMID: 33675109.
Copy Download .nbib Format: NLM
Showing 49 to 52 of 52 entries